IP Library › Granted Patent US 7,910,369
Granted Patent B2
US 7,910,369 · App. 11/211,174 · Granted Mar 22, 2011

Culture systems for ex vivo development

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,369
App. No.
11/211,174
Granted
Mar 22, 2011
Kind
B2
Abstract

The present invention provides methods for the culture of animal pluripotent stem cells and their differentiated progeny cells, tissues, and organs, and nonhuman animal embryos and fetuses.

Claims (14)

1. A method of maintaining human pluripotent stem cells in an undifferentiated state comprising co-culturing said human pluripotent stem cells with chick embryonic fibroblasts feeder cells, wherein the chick embryonic fibroblast feeder cells are obtained from an eviscerated embryo with the embryo's head left on.

2. The method of claim 1 , wherein the chick embryonic fibroblasts feeder cells are specific pathogen-free.

3. The method of claim 1 , wherein the human pluripotent stem cells are human embryonic stem cells.

4. The method of claim 2 , wherein the human pluripotent stem cells are human embryonic stem cells.

5. The method of claim 1 , wherein the chick embryonic fibroblast feeder cells are used at passage two.

6. The method of claim 2 , wherein the chick embryonic fibroblast feeder cells are used at passage two.

7. A method of maintaining human pluripotent stem cells in an undifferentiated state comprising co-culturing said human pluripotent stem cells with chick embryonic fibroblasts feeder cells, wherein the chick embryonic fibroblast feeder cells are used at passage two.

8. The method of claim 7 , wherein the chick embryonic fibroblasts feeder cells are specific pathogen-free.

9. The method of claim 7 , wherein the human pluripotent stem cells are human embryonic stem cells.

10. The method of claim 8 , wherein the human pluripotent stem cells are human embryonic stem cells.

11. A method of maintaining human pluripotent stem cells in an undifferentiated state comprising co-culturing said human pluripotent stem cells with chick embryonic fibroblasts feeder cells, wherein the chick embryonic fibroblast feeder cells were derived from a 7 or 8-day embryo.

12. The method of claim 11 , wherein the chick embryonic fibroblasts feeder cells are specific pathogen-free.

13. The method of claim 11 , wherein the human pluripotent stem cells are human embryonic stem cells.

14. The method of claim 12 , wherein the human pluripotent stem cells are human embryonic stem cells.

Assignments (5)
CHANGE OF NAME Recorded Feb 16, 2018
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 045356/0244 →
CHANGE OF NAME Recorded Feb 15, 2018
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 045347/0365 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2014
From: CAMOFI MASTER LDC; CAMHZN MASTER LDC
To: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
Reel/Frame 034421/0863 →
SECURITY AGREEMENT Recorded Jan 25, 2013
From: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
To: CAMOFI MASTER LDC; CAMHZN MASTER LDC
Reel/Frame 029698/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2008
From: WEST, MICHAEL D.; CHAPMAN, KAREN B.; KLIMANSKAYA, IRINA V.
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 022000/0288 →